Imperial College London reaches 'significant milestone' after safely delivering first dose of coronavirus vaccine

Imperial College London coronavirus vaccine development.
(Image credit: TOLGA AKMEN/AFP via Getty Images)

Imperial College London has "reached a significant milestone" after delivering a small dose of its coronavirus vaccine candidate to the first healthy volunteer in its trial. So far, all has gone according to plan. The clinical team is closely monitoring the participant's health, which remains in good condition, and there are no safety concerns.

Developing a vaccine for the COVID-19 virus is crucial during the pandemic, and it's worth keeping an eye on every effort. But Imperial College's candidate stands out because it's based on a new self-amplifying RNA technology, which has never before been involved in human trials. If it proves safe and effective, Imperial College believes it could revolutionize — and reduce the cost of — vaccine development, allowing scientists to take on emerging diseases like COVID-19 much more quickly in the future.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.